Fannie Mae, Freddie Mac shares tumble after conservatorship comments
AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN) has released its block listing interim review, detailing the status of its share schemes as of June 2, 2025. The pharmaceutical company, headquartered in Cambridge, UK, provided information on several of its share option plans, including the AstraZeneca (NASDAQ:AZN) Share Option Plan, Savings-Related Share Option Plan, All-Employee Share Plan, and the 2012 Savings-Related Share Option Scheme.
The report, covering the period from December 1, 2024, to May 31, 2025, indicates a balance of 4,029,156 unallotted securities from the previous return. During this period, AstraZeneca issued 340,773 securities under the schemes. Consequently, the balance of securities not yet issued or allotted at the end of the period stands at 3,688,383.
No increase in the block scheme was reported since the last return. The review is part of AstraZeneca’s regulatory requirements and was submitted in compliance with the Securities Exchange Act of 1934.
AstraZeneca, a global biopharmaceutical company, focuses on the development and commercialization of prescription medicines in various therapeutic areas, including oncology and rare diseases. The information was disclosed in a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.